Literature DB >> 10575403

Seroprevalence rates of antibodies to phenolic glycolipid-I among school children as an indicator of leprosy endemicity.

S van Beers1, M Hatta, P R Klatser.   

Abstract

In order to study whether the seroprevalence of antibodies to phenolic glycolipid-I (PGL-I) among school children is a useful indicator of the leprosy problem in certain areas, school surveys were carried out. These surveys have the advantage of targeting an easily accessible, stable and standardized population. Antibodies to the species-specific PGL-I of Mycobacterium leprae were detected in a simple gelatin particle agglutination test. We have determined the seroprevalence rates in 2835 school children from five different areas in three provinces of Sulawesi, Indonesia. Three areas with a case-detection rate of over 3.4/10,000 were designated as high-endemic areas. The other two were designated as low-endemic areas, having a case-detection rate of less than 1/10,000. The seroprevalence rates in the three high-endemic areas ranged from 26% to 28% (95% CI 21%-31%). In both low-endemic areas the seroprevalence rate was 7% (95% CI 5%-10%). In a second survey conducted in one high-endemic area 3 years after the first survey, the seroprevalence rate was the same as in the first survey. These results indicate that seropositivity rates among school children may reflect the leprosy incidence. They illustrate the potential applicability of seroprevalence as an indicator of the magnitude of the leprosy problem in a selected area.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10575403

Source DB:  PubMed          Journal:  Int J Lepr Other Mycobact Dis        ISSN: 0148-916X


  7 in total

1.  Risk and protective factors for leprosy development determined by epidemiological surveillance of household contacts.

Authors:  Isabela M B Goulart; Dulcinéa O Bernardes Souza; Carolina R Marques; Vânia L Pimenta; Maria A Gonçalves; Luiz R Goulart
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

2.  Serological diagnosis of leprosy in patients in vietnam by enzyme-linked immunosorbent assay with Mycobacterium leprae-derived major membrane protein II.

Authors:  Masanori Kai; Nhu Ha Nguyen Phuc; Thuy Huong Hoang Thi; An Hoang Nguyen; Yasuo Fukutomi; Yumi Maeda; Yuji Miyamoto; Tetsu Mukai; Tsuyoshi Fujiwara; Tan Thanh Nguyen; Masahiko Makino
Journal:  Clin Vaccine Immunol       Date:  2008-10-22

3.  Geographical heterogeneity in the analysis of factors associated with leprosy in an endemic area of Brazil: are we eliminating the disease?

Authors:  Mônica Duarte-Cunha; Geraldo Marcelo da Cunha; Reinaldo Souza-Santos
Journal:  BMC Infect Dis       Date:  2015-04-25       Impact factor: 3.090

4.  Recombinant polypeptide of Mycobacterium leprae as a potential tool for serological detection of leprosy.

Authors:  Marcelo Dos Santos Barbosa; Iara Beatriz Andrade de Sousa; Simone Simionatto; Sibele Borsuk; Silvana Beutinger Marchioro
Journal:  AMB Express       Date:  2019-12-17       Impact factor: 3.298

5.  Synthetic Phenolic Glycolipids for Application in Diagnostic Tests for Leprosy.

Authors:  J Hessel M van Dijk; Anouk van Hooij; L Melanie Groot; Jolijn Geboers; Rosita Moretti; Els Verhard-Seymonsbergen; Danielle de Jong; Gijs A van der Marel; Paul L A M Corstjens; Jeroen D C Codée; Annemieke Geluk
Journal:  Chembiochem       Date:  2021-02-10       Impact factor: 3.164

6.  Spatial analysis spotlighting early childhood leprosy transmission in a hyperendemic municipality of the Brazilian Amazon region.

Authors:  Josafá Gonçalves Barreto; Donal Bisanzio; Layana de Souza Guimarães; John Stewart Spencer; Gonzalo M Vazquez-Prokopec; Uriel Kitron; Claudio Guedes Salgado
Journal:  PLoS Negl Trop Dis       Date:  2014-02-06

7.  Evidence of hidden leprosy in a supposedly low endemic area of Brazil.

Authors:  Fred Bernardes; Natália Aparecida de Paula; Marcel Nani Leite; Thania Loyola Cordeiro Abi-Rached; Sebastian Vernal; Moises Batista da Silva; Josafá Gonçalves Barreto; John Stewart Spencer; Marco Andrey Cipriani Frade
Journal:  Mem Inst Oswaldo Cruz       Date:  2017-12       Impact factor: 2.743

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.